Head-to-head · WeighScore
Fierce Health vs Tell Her Doc
The verdict
Tell Her Doc takes it — 57.4/100 to 56.6/100, but only just.
Tell Her Doc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tell Her Doc is a women-focused, self-pay telehealth program for compounded GLP-1 weight loss — compounded semaglutide and tirzepatide in injection, oral, and orally-dissolving-tablet forms, plus microdoses. Fierce Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fierce Health | Tell Her Doc |
|---|---|---|
| WeighScore | 56.6/100 | 57.4/100 |
| Grade | C | C |
| Scorecard rank | #410 | #400 |
| Semaglutide | $297/mo (3-month plan, compounded) | $269/mo (microdose tier, plus a separate fee, compounded) |
| Tirzepatide | $497/mo (3-month plan, compounded) | Not disclosed |
| Coverage | 30 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #410 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #400 · C
Strengths
- Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
- Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
- No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
- Serves patients in all 50 states via a private online consultation
Where it loses points
- 'All sales are final' — no refunds once medication has left the pharmacy
- Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
- References LegitScript but without an independently verifiable seal — we couldn't confirm certification
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.